BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 9849691)

  • 1. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
    Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
    Cornelissen JJ; Fibbe WE; Schattenberg AV; Petersen EJ; Willemze R; de Witte TJ; Löwenberg B; Verdonck LF; vd Biezen A; Brand R
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S66-70. PubMed ID: 9712499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
    Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
    Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
    Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
    Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
    Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells.
    Briones J; Urbano-Ispizua A; Lawler M; Rozman C; Gardiner N; Marín P; Salgado C; Féliz P; McCann S; Montserrat E
    Exp Hematol; 1998 May; 26(5):415-20. PubMed ID: 9590658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
    Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
    Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
    Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk.
    Miflin G; Russell NH; Hutchinson RM; Morgan G; Potter M; Pagliuca A; Marsh J; Bell A; Milligan D; Lumley M; Cook G; Franklin I
    Bone Marrow Transplant; 1997 Jan; 19(1):9-13. PubMed ID: 9012925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.